Noveltreat Patient Profile Matcher

---
name: noveltreat-patient-profile-matcher
description: Match an adult obese patient to the best-fit evidence anchor for Noveltreat (semaglutide 2.4 mg) using the 7 Sun Pharma monograph obesity profiles — medically-supervised weight loss, obese + uncontrolled T2DM, obese + CVD / HFpEF risk, obese + knee osteoarthritis, obese + MASH, obese + prediabetes, and obese + PCOS. Use when a clinician describes a candidate for semaglutide 2.4 mg and wants the matching STEP / SELECT / STEP-HFpEF / ESSENCE / STEP 9 / STEP 10 trial with key numbers, clinical concerns, and the "why Noveltreat" rationale. Grounded in Sun Pharmaceutical Industries Ltd. Product Monograph — Diabetes and Obesity (2026).
---

# Noveltreat — Patient Profile Matcher (Obesity, semaglutide 2.4 mg)

## How to Use

1. Read the patient's description (age, sex, BMI, HbA1c, comorbidities, current therapy).
2. Match to **one of the 7 profiles** below — pick the profile whose dominant feature matches.
3. Return: anchor trial + key numbers + clinical concerns + why Noveltreat fits.
4. If the patient fits > 1 profile, list each in priority order and name the primary driver.

---

## Profile 1 — Obese patient seeking medically-supervised weight loss

- **Typical patient:** BMI ≥ 30 (or ≥ 27 + comorbidity), no T2DM, failed diet/exercise alone, no prior anti-obesity pharmacotherapy.
- **Concerns:** weight beyond what diet/exercise achieves; sustained weight + waist reduction; safe long-term pharmacotherapy.
- **Anchor trials:** STEP 1, 3, 4, 5.
- **Key numbers:**
  - Weight: **−14.9 to −17.4 %** at 68 weeks (STEP 4)
  - **69.1 %** ≥ 10 % loss; **50.5 %** ≥ 15 % loss
  - Waist circumference: **−14.6 cm**
  - STEP 5 (104 weeks): sustained **−15.2 %**, 77.1 % with ≥ 5 % loss
  - STEP 4 withdrawal: continued semaglutide −7.9 % vs placebo +6.9 %
- **Why Noveltreat:** central appetite suppression, durable loss to 2 years, improved cardiometabolic risk, simple once-weekly dosing.

---

## Profile 2 — Obese patient with uncontrolled T2DM

- **Typical patient:** BMI ~ 31, HbA1c ~ 7.8 %, on metformin ± SGLT2, persistent hyperglycemia and weight issues.
- **Concerns:** glycemic gap, weight persistence, long-term cardiometabolic risk, adherence.
- **Anchor trial:** STEP 2.
- **Key numbers:**
  - Weight: **−9.6 %** (vs −3.4 % placebo; p < 0.0001)
  - HbA1c: **−1.6 %** (from 8.1 %)
  - **68.8 %** achieved ≥ 5 % weight loss
- **Why Noveltreat:** meaningful HbA1c reduction alongside weight loss; RSSDI / ADA endorse GLP-1 RA escalation when HbA1c 7–9 % on dual/dual+ with persistent weight issues; high compliance.

---

## Profile 3 — Obese patient with established CVD and/or HFpEF risk

- **Typical patient:** BMI ~ 33, prior MI, high HFpEF risk, dyslipidemia/HTN/prediabetes.
- **Concerns:** recurrent CV risk, HFpEF progression, functional capacity, disease-modifying therapy.
- **Anchor trials:** SELECT, STEP-HFpEF (obesity + T2DM), STEP-HFpEF (no DM), STEP 5.
- **Key numbers:**
  - **MACE ↓ 20 %** over 39 months vs placebo (SELECT)
  - Weight: **−8.51 %**; CRP **−43.5 %**
  - 6-minute walk distance: **+21.5 m**
  - KCCQ-CSS: **+16.6** points (vs +8.7 placebo); 32.3 % achieved ≥ 15-point improvement at week 52
  - STEP 5: 77.1 % ≥ 5 % weight loss at week 104
- **Why Noveltreat:** CV benefit independent of T2DM; improved HFpEF symptoms, physical function, QoL; addresses weight + inflammation + CV risk simultaneously; aligned with ACC 2025 / ESC guidelines.

---

## Profile 4 — Obese patient with knee osteoarthritis

- **Typical patient:** BMI ~ 34, chronic knee pain, limited mobility, unable to exercise adequately.
- **Concerns:** meaningful weight loss despite exercise limitation, reduction in pain and functional impairment, long-term adherence.
- **Anchor trial:** STEP 9.
- **Key numbers:**
  - Weight: **−13.7 %** (vs −3.2 % placebo) at 68 weeks
  - WOMAC pain score: **−41.7** points (vs −27.5 placebo); > 50 % achieved ≥ 41.2-point improvement
  - SF-36 physical function: **+12** points (vs +6.5 placebo)
- **Why Noveltreat:** substantial weight loss reduces mechanical knee stress; improves physical function and mobility scores; enables gradual re-engagement in activity; once-weekly simplicity.

---

## Profile 5 — Obese patient with MASH (metabolic dysfunction-associated steatohepatitis)

- **Typical patient:** BMI ~ 31, F2 fibrosis, prediabetes (HbA1c ~ 6.4 %), metabolic syndrome, on metformin ± pioglitazone.
- **Concerns:** halting fibrosis, steatohepatitis resolution, safe option in multi-morbid patient.
- **Anchor trial:** ESSENCE (interim analysis at week 72).
- **Key numbers:**
  - Fibrosis reduction: **36.8 %** (vs 22.4 % placebo)
  - MASH resolution without fibrosis worsening: **62.9 %** (vs 34.3 %); absolute difference 28.7 %, p < 0.001
  - Combined steatohepatitis resolution + fibrosis reduction: **32.7 %** (vs 16.1 %); absolute difference 14.4 %, p < 0.001
  - Weight: **−10.5 %**
- **Why Noveltreat:** currently the only FDA-approved glucose-lowering / obesity medication for MASH; improves insulin resistance, liver inflammation, cardiometabolic markers; low hypoglycemia risk.

---

## Profile 6 — Obese patient with prediabetes

- **Typical patient:** BMI ~ 32, HbA1c ~ 6.1 %, FPG ~ 110 mg/dL, Class I obesity, mild dyslipidemia/HTN.
- **Concerns:** effective weight loss beyond lifestyle, prevention-focused intervention, adherence.
- **Anchor trial:** STEP 10.
- **Key numbers:**
  - **81 %** reversion to normoglycemia (vs 14 % placebo)
  - Weight: **−13.9 %** (vs −2.7 % placebo)
- **Why Noveltreat:** produces substantial sustained weight loss > 10 %; improves insulin sensitivity; facilitates reversion from prediabetes to normoglycemia.

---

## Profile 7 — Obese patient with PCOS

- **Typical patient:** BMI ~ 33, irregular / oligomenorrhoeic cycles, insulin-resistant, ≥ 6 months of structured lifestyle with inadequate response, on metformin.
- **Concerns:** sustained weight loss, insulin resistance, menstrual regularity, hyperandrogenism, fertility goals.
- **Anchor trials:** STEP 1, STEP 5, and obesity-PCOS study (semaglutide 0.5 mg SC, 3 months).
- **Key numbers:**
  - PCOS study: mean weight −7.6 kg, BMI −3.1 kg/m², −8.9 % body weight at 3 months
  - **80 %** of patients on 0.5 mg semaglutide had regular menstrual cycles
  - STEP 1: 32 % achieved ≥ 20 % weight loss at 68 weeks
  - STEP 5: 36.1 % ≥ 20 % loss at 104 weeks; fasting insulin **−32.7 %** vs −7.2 % placebo
- **Why Noveltreat:** meaningful sustained weight loss is central to improving PCOS pathophysiology; helps maintain loss long-term; improves waist circumference, metabolic and inflammatory markers.

---

## Output Template

When returning a match, use this structure:

```
Best-fit profile: <n>. <profile name>
Anchor trial(s): <trial names>
Expected outcomes: <key numbers for this profile>
Why Noveltreat fits: <3–5 bullet rationale>
Caveats: <relevant contraindications or monitoring>
→ Dose and start: see `noveltreat-prescribing-guide`
```

If the patient has T2DM + CKD instead of obesity focus, note that Noveltreat is the **obesity brand** — Sematrinity is the T2DM brand; recommend checking the companion T2DM profile sheet.

## Reference

Sun Pharmaceutical Industries Ltd. **Product Monograph — Diabetes and Obesity (Sematrinity® and Noveltreat®)**, 2026 (Data on file).